Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses the Next Steps for Ipilimumab
Axel Hoos, MD, PhD
Advertisement
Articles by Axel Hoos, MD, PhD
Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses Which Patients are Eligible to Receive Ipilimumab
Dr. Axel Hoos medical lead at bristol-myers squibb on the Ipilimumab Plus Dacarbazine Combination Trial
Dr. Axel Hoos medical lead at Bristol-Myers Squibb on Why Melanoma is Amenable to Immunotherapy
Dr. Axel Hoos from Bristol-Myers Squibb Explains the Future of Immunotherapy and Ipilimumab's role
Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies
Dr. Axel Hoos from Bristol Myers-Squibb on Tools Available to Measure Ipilimumab's Success
Dr. Axel Hoos the medical lead in Immunology/Oncology at Bristol-Myers Squibb Discusses the Clinical Kinetics of Immunotherapy
Dr. Axel Hoos Medical Lead in Immunology/Oncology at Bristol-Myers Squibb on a Possible Successor Drug to Ipilimumab
Dr. Hoos From Bristol-Myers Squibb Discusses Key Points of the Ipilimumab Trial
Dr. Axel Hoos from Bristol Myers-Squib on the Patients That Respond to Ipilimumab
Advertisement
Latest Updated Articles
Dr. Hoos Discusses Key Points of the Ipilimumab TrialJune 15th 2011
Dr. Hoos on a Possible Successor Drug to IpilimumabJune 22nd 2011
Dr. Hoos Discusses the Next Steps for IpilimumabAugust 9th 2011
Dr. Hoos Describes Ipilimumab and Future ImmunotherapiesJuly 13th 2011
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers
5